Document is current
Any future updates will be listed below
-
Authors
Ngo, Wayne https://orcid.org/0000-0002-5755-2303
Wu, Jamie L. Y.
Wasko, Kevin M.
Doudna, Jennifer A. https://orcid.org/0000-0001-9161-999X
-
Funding
Funding for this research was provided by:
DOE | LDRD | Lawrence Livermore National Laboratory (DE-AC52-07NA27344)
Funding was also provided by the Howard Hughes Medical Institute and Gladstone Institutes.
Funded by the Natural Sciences and Engineering Research Council of Canada Postdoctoral Fellowship
- License Information
-
More Information
Article History
Received: 21 August 2025
Accepted: 4 November 2025
First Online: 12 January 2026
Competing interests
: The Regents of the University of California have patents issued and/or pending for CRISPR technologies (on which J.A.D. is an inventor) and delivery technologies (on which J.A.D. and W.N. are co-inventors). J.A.D. is a cofounder of Azalea Therapeutics, Caribou Biosciences, Editas Medicine, Evercrisp, Scribe Therapeutics and Mammoth Biosciences. J.A.D. is a scientific advisory board member at Isomorphic Labs, BEVC Management, Evercrisp, Caribou Biosciences, Scribe Therapeutics, Mammoth Biosciences, The Column Group and Inari. She is also an advisor for Aditum Bio. J.A.D. is chief science advisor to Sixth Street, is a director at Johnson & Johnson, Altos and Tempus, and has a research project sponsored by Apple Tree Partners. All other authors declare no competing interests.
